Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

845 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients.
Franken A, Honisch E, Reinhardt F, Meier-Stiegen F, Yang L, Jaschinski S, Esposito I, Alberter B, Polzer B, Huebner H, Fasching PA, Pancholi S, Martin LA, Ruckhaeberle E, Schochter F, Tzschaschel M, Hartkopf AD, Mueller V, Niederacher D, Fehm T, Neubauer H. Franken A, et al. Among authors: fasching pa. J Mol Diagn. 2020 Jan;22(1):111-121. doi: 10.1016/j.jmoldx.2019.09.004. Epub 2019 Oct 24. J Mol Diagn. 2020. PMID: 31669227 Free article.
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Zeitz J, Pantel K, Fehm T; DETECT study group. Müller V, et al. Among authors: fasching pa. Breast Cancer Res. 2011 Jul 11;13(4):R71. doi: 10.1186/bcr2916. Breast Cancer Res. 2011. PMID: 21745383 Free PMC article.
Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T; DETECT study group. Müller V, et al. Among authors: fasching pa. Breast Cancer Res. 2012 Aug 15;14(4):R118. doi: 10.1186/bcr3243. Breast Cancer Res. 2012. PMID: 22894854 Free PMC article.
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.
Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, Friedl TW, Lorenz R, Tesch H, Fasching PA, Fehm T, Schneeweiss A, Lichtenegger W, Beckmann MW, Friese K, Pantel K, Janni W; SUCCESS Study Group. Rack B, et al. Among authors: fasching pa. J Natl Cancer Inst. 2014 May 15;106(5):dju066. doi: 10.1093/jnci/dju066. J Natl Cancer Inst. 2014. PMID: 24832787 Free PMC article. Clinical Trial.
Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies.
Salmen J, Neugebauer J, Fasching PA, Haeberle L, Huober J, Wöckel A, Rauh C, Schuetz F, Weissenbacher T, Kost B, Stickeler E, Klar M, Orlowska-Volk M, Windfuhr-Blum M, Heil J, Rom J, Sohn C, Fehm T, Mohrmann S, Loehberg CR, Hein A, Schulz-Wendtland R, Hartkopf AD, Brucker SY, Wallwiener D, Friese K, Hartmann A, Beckmann MW, Janni W, Rack B. Salmen J, et al. Among authors: fasching pa. Breast Cancer Res Treat. 2014 Nov;148(1):143-51. doi: 10.1007/s10549-014-3130-4. Epub 2014 Sep 25. Breast Cancer Res Treat. 2014. PMID: 25253172
Molecular profiling of single circulating tumor cells with diagnostic intention.
Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A, Andergassen U, Meier-Stiegen F, Czyz ZT, Alberter B, Treitschke S, Schamberger T, Sergio M, Bregola G, Doffini A, Gianni S, Calanca A, Signorini G, Bolognesi C, Hartmann A, Fasching PA, Sandri MT, Rack B, Fehm T, Giorgini G, Manaresi N, Klein CA. Polzer B, et al. Among authors: fasching pa. EMBO Mol Med. 2014 Nov;6(11):1371-86. doi: 10.15252/emmm.201404033. EMBO Mol Med. 2014. PMID: 25358515 Free PMC article.
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.
Hein A, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer JU, Schwedler K, Kittel K, Fehm T, Kunz G, Beckmann MW, Ekici AB, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilboum RM, Loibl S, Fasching PA. Hein A, et al. Among authors: fasching pa. Int J Cancer. 2015 Dec 15;137(12):2981-8. doi: 10.1002/ijc.29656. Epub 2015 Jul 6. Int J Cancer. 2015. PMID: 26100253 Clinical Trial.
845 results